Datsun Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 17-07-2024
- Paid Up Capital ₹ 0.10 M
as on 17-07-2024
- Company Age 24 Year, 11 Months
- Last Filing with ROC 31 Mar 2020
- Revenue %
(FY 2020)
- Net Worth -260.00%
(FY 2020)
- Total Assets %
(FY 2020)
About Datsun Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Kullanakoppalu Shridhar and Avantika Velho serve as directors at the Company.
- CIN/LLPIN
U52311GA2000PTC002786
- Company No.
002786
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Jan 2000
- Date of AGM
31 Dec 2020
- Date of Balance Sheet
31 Mar 2020
- Listing Status
Unlisted
- ROC Code
Roc Goa
Industry
Company Details
- Location
Vasco Da Gama, Goa, Goa, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Datsun Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kullanakoppalu Shridhar  | Director | 18-Jul-2019 | Current |
| Avantika Velho | Director | 07-Aug-2020 | Current |
Financial Performance and Corporate Structure Insights of Datsun Pharmaceuticals.
Datsun Pharmaceuticals Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth observed a substantial decline by a decrease of 260%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Datsun Pharmaceuticals?
In 2020, Datsun Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Velho Microbrew Private LimitedActive 14 years 2 monthsKullanakoppalu Shridhar and Avantika Velho are mutual person
- Velho Construction Company Private LimitedActive 15 years 7 months
Kullanakoppalu Shridhar and Avantika Velho are mutual person
- Ashvem Spa And Resorts Private LimitedActive 15 years 9 months
Kullanakoppalu Shridhar and Avantika Velho are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Datsun Pharmaceuticals?
Unlock and access historical data on people associated with Datsun Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Datsun Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Datsun Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
